NMDA RECEPTOR AS THERAPEUTIC TARGET FOR PARKINSON?S DISEASE

NMDA 受体作为帕金森病的治疗靶点

• 批准号: 7958260
• 负责人: STELLA PAPPA
• 金额: $ 4.39万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958260
• 关键词: Animal Model; Computer Retrieval of Information on Scientific Projects Database; Dopamine; Funding; Grant; Institution; Lesion; Motor; N-Methyl-D-Aspartate Receptors; Parkinson Disease; Parkinsonian Disorders; Primates; Rattus; Research; Research Personnel; Resources; Source; Symptoms; United States National Institutes of Health; Work; in vivo; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to obtain in vivo proof that blockade of NR2D-containing NMDA receptors has beneficial actions on parkinsonian motor symptoms in an animal model of Parkinson's disease, the 6-OH-dopamine-lesioned rat. Work on this project just recently started.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是获得体内证据，证明阻断含有 NR2D 的 NMDA 受体对帕金森病动物模型（6-OH-多巴胺损伤大鼠）的帕金森运动症状具有有益作用。该项目的工作最近刚刚开始。